ATYR Stock Analysis: Buy, Sell, or Hold?
ATYR - aTyr Pharma, Inc. Common Stock
$0.54
0.07 (14.23%)
▲
5d:
+21.16%
30d:
+1.63%
90d:
-35.09%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When ATYR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ATYR shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ATYR shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ATYR is currently trading at $0.54, which is considered extended relative to its 30-day fair value range of $0.46 to $0.52.
Technical Outlook: Technically, ATYR is in a strong downtrend. Immediate support is located at $0.44, while resistance sits at $0.56. The stock is showing strong short-term momentum, up 14.2% recently.
Market Sentiment: ATYR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $2.86 (+431.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ATYR is in a strong downtrend. Immediate support is located at $0.44, while resistance sits at $0.56. The stock is showing strong short-term momentum, up 14.2% recently.
Market Sentiment: ATYR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $2.86 (+431.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.46 -
$0.52
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
68.4%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+14.2%)
- BULLISH: Trading 431.9% below Wall St target ($2.86)
Trading Range Analysis
30-Day Trading Range
$0.46 -
$0.52
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.44
Resistance Level
$0.56
Current Trend
Strong Downtrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.92
Wall Street Target
$2.86
(+431.9%)
Share & Embed Analysis
Last updated: June 24, 2026 6:17 AM ET
Data refreshes hourly during market hours. Next update: 7:17 AM
Data refreshes hourly during market hours. Next update: 7:17 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ATYR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Jill Marie Broadfoot
SELL
1558 shares
2026-02-04
Nancy Denyes
SELL
1118 shares
2026-02-04
Sanjay Shukla
SELL
3745 shares
2026-02-04
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 67 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$105 | 64 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 61 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 65 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 65 BUY |
